Disease · MONDO_0005419
methamphetamine dependence
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. methamphetamine dependence. Diseases, record MONDO_0005419. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005419
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- methamphetamine dependence
- Open Targets ID
- MONDO_0005419
- Other names
- Amphetamine-Related Disorders, metamphetamine addiction
- Highest stage of its drugs
- Phase 3, for 3 of its 30 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs30
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUPROPION | CHEMBL894 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CITICOLINE | CHEMBL1231700 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MODAFINIL | CHEMBL1373 | Small molecule | Phase 2 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| VARENICLINE | CHEMBL1076903 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| MIRTAZAPINE | CHEMBL654 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| IBUDILAST | CHEMBL19449 | Small molecule | Phase 2 | ClinicalTrials.gov and TTD | 3 | 2 | 2 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| DEXTROAMPHETAMINE | CHEMBL612 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| METHYLPHENIDATE | CHEMBL796 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 30
See all 30 drugsTargets80
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A2 | Monoamine transporter | 6 | Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| SLC6A3 | Monoamine transporter | 6 | Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6531 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 5 | Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 3 | Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2559 | Drugs and targets |
1 to 10 of 80
See all 80 targetsTrials55
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03078075 | Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder | Phase 3 | 403 | 2021-03-29 | Methamphetamine Use Disorder | BUPROPION, NALTREXONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00520286 | Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence | Phase 2 | 210 | 2017-04-07 | Methamphetamine Dependence | MODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT00687713 | Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence | Phase 2 | 200 | 2017-02-15 | Methamphetamine Dependence | BUPROPION | Its record names the disease | ClinicalTrials.gov |
| NCT00345371 | Topiramate for the Treatment of Methamphetamine Dependence - 1 | Phase 2 | 140 | 2017-02-23 | Methamphetamine | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT01860807 | Trial of Ibudilast for Methamphetamine Dependence | Phase 2 | 125 | 2019-01-30 | Methamphetamine Dependence, HIV Infection | IBUDILAST | Its record names the disease | ClinicalTrials.gov |
| NCT00950352 | Citicoline Treatment of Methamphetamine Dependence | Phase 3 | 104 | 2015-02-11 | Methamphetamine Dependence | CITICOLINE | Its record names the disease | ClinicalTrials.gov |
| NCT00497055 | Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals | Phase 2 | 90 | 2014-03-24 | Substance Abuse, HIV Infections | ARIPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT00571922 | A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction | Phase 1/2 | 72 | 2016-04-06 | Methamphetamine Dependence, Treatment Seeking | ACAMPROSATE | Its record names the disease | ClinicalTrials.gov |
| NCT00469508 | Modafinil vs Placebo for the Treatment of Methamphetamine Dependence | Phase 2 | 71 | 2013-03-15 | Methamphetamine Dependence | MODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT00497081 | Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors | Phase 2 | 60 | 2014-10-20 | Substance Abuse, HIV Infections | MIRTAZAPINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 55
See all 55 trialsComparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Modafinil vs Placebo: Reduction of Craving | 32 of 142 | 10 of 68 | 210 | NCT00520286 | Trial comparisons |
| Modafinil vs Placebo: serious adverse events | 0 of 142 | 5 of 68 | 210 | NCT00520286 | Trial comparisons |
| Bupropion vs Placebo: Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use | 65 of 100 | 76 of 104 | 204 | NCT00687713 | Trial comparisons |
| Bupropion vs Placebo: Number of Subjects Showing Abstinence | 14 of 100 | 20 of 104 | 204 | NCT00687713 | Trial comparisons |
| Bupropion vs Placebo: serious adverse events | 1 of 100 | 3 of 104 | 204 | NCT00687713 | Trial comparisons |
| Topiramate vs Placebo Oral Tablet: serious adverse events | 3 of 69 | 8 of 71 | 140 | NCT00345371 | Trial comparisons |
| Ibudilast vs Placebo: Methamphetamine Use | 9 of 64 | 10 of 61 | 125 | NCT01860807 | Trial comparisons |
| Ibudilast vs Placebo: deaths from any cause | 0 of 64 | 0 of 61 | 125 | NCT01860807 | Trial comparisons |
| Ibudilast vs Placebo: serious adverse events | 2 of 64 | 1 of 61 | 125 | NCT01860807 | Trial comparisons |
| Citicoline vs Placebo: serious adverse events | 2 of 72 | 0 of 32 | 104 | NCT00950352 | Trial comparisons |
1 to 10 of 33
See all 33 comparisons in its trialsPapers from its trials24
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005419
GET https://conductscience.org/api/diseases/v1/MONDO_0005419/drugs?page=2